Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape
Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...
Fintel on MSN23h
Morgan Stanley Downgrades Third Harmonic Bio (THRD)
Fintel reports that on February 12, 2025, Morgan Stanley downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from ...
The Pharma Letter23h
Third Harmonic and Inventiva slash workforces
American biotech Third Harmonic Bio and Inventiva have announced plans to reduce their respective workforces by 50% as part of cost-cutting measures. Both companies are shifting their focus to a ...